ArticleJournal of translational medicine2026
Differential laboratory monitoring in autoimmune disease: a matched case-control study from Qatar primary care.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo examine whether patients with autoimmune diseases receive differential cardiometabolic and inflammatory laboratory monitoring compared to matched controls in primary care, and to identify predictors of monitoring patterns.
methodsWe conducted a matched case-control study using electronic health records from the Primary Health Care Corporation (PHCC), Qatar (January 2015 to December 2024). Adults with Hashimoto's thyroiditis, rheumatoid arthritis (RA), or systemic lupus erythematosus (SLE) were matched 1:2 to controls without autoimmune disease on age and sex. Primary outcomes were receipt of cardiometabolic tests (haemoglobin A1c [HbA1c], complete lipid panel) and inflammatory markers (C-reactive protein [CRP], erythrocyte sedimentation rate [ESR]). We used conditional logistic regression adjusting for comorbidities, medications, and healthcare utilisation.
resultsAmong 27,911 participants (9,356 cases, 18,555 controls; mean age 46.7 years; 74.4% female) in 9,356 matched sets, we observed divergent monitoring patterns. Compared to controls, patients with RA had significantly lower odds of HbA1c monitoring (OR 0.77, 95% CI 0.69-0.85) and complete lipid panels (OR 0.74, 95% CI 0.67-0.82). Similar patterns were observed for SLE (HbA1c: OR 0.67, 95% CI 0.57-0.80; lipid: OR 0.60, 95% CI 0.51-0.70). Conversely, RA patients had 4.2-fold higher odds of CRP testing and 4.4-fold higher odds of ESR testing; SLE patients showed similar elevations (3.7-fold and 4.2-fold, respectively). Hashimoto's patients showed modestly increased monitoring across all test types (HbA1c: OR 1.45, 95% CI 1.23-1.70).
conclusionsDespite elevated cardiovascular risk, patients with systemic autoimmune diseases (RA, SLE) receive less cardiometabolic laboratory monitoring than matched controls while receiving substantially more inflammatory marker testing. This differential monitoring pattern - which we describe as a "monitoring gap paradox" and which persisted across sensitivity analyses - is consistent with care coordination challenges at the primary care-specialty interface. The observational design precludes inferences about the underlying causes, but the findings identify a potential quality improvement opportunity warranting further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.